VolitionRx Announces Internal Clinical Study for Nucleosomics Diagnostic Products

VolitionRx Limited

, announces that it will commence a large internal clinical study for its Nucleosomics diagnostic products this month. This trial is being undertaken in addition to its four ongoing external clinical trials. The trial will be carried out in Volition's laboratory on patient blood samples supplied by the Wales Cancer Bank (www.walescancerbank.com), which is based in Cardiff, in the United Kingdom. Beginning late January, NuQ tests will be conducted on blood samples taken from more than 800 cancer patients by the Wales Cancer Bank as well as healthy control volunteers. The expected sample distribution is as follows: Breast cancer: approx. 550 patients with a variety of subtypes, including invasive ductal carcinoma, invasive lobular and tubular carcinomas, and in-situ carcinoma ductal Colorectal cancer: approx. 230 patients with a variety of subtypes, at various stages from Stage A to Stage D Plus smaller numbers of patients with lung and pancreatic cancers. The study follows a highly successful pilot study on 100 patient samples from the Wales Cancer Bank, (results of which were announced in December 2012), after which Volition was awarded scientific approval from the Bank for